Elekta recently announced that it will purchase Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent portfolio.
Financial terms of the deal were not disclosed in the May 3 news release.
Stockholm-based Elekta said the deal bolsters its position in treatment planning as it seeks to be the innovation leader in radiation therapy. By integrating the technologies covered by the acquired patent portfolio, the two companies aim to offer a seamless and best-in-class transition for existing Pinnacle users to Elekta One Planning, including data conversion services, according to the companies.
“Thanks to continued investments over the years, our treatment planning system supports both Elekta and non-Elekta devices, including proton therapy, making Elekta One Planning one of the most competitive solutions in the market,” Maurits Wolleswinkel, president of Linac and Software Solutions at the Swedish company, said in the news release.
The two companies agreed in 2021 to deepen their cancer treatment tech partnership.
Martijn Hartjes, business leader of Clinical Informatics at Philips, said selling the patents was a logical next step in the companies’ long-term collaboration to improve cancer radiotherapy.”We are pleased that we can continue to support our customers with leading solutions in radiation oncology.”
